)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
scPharmaceuticals
scPharmaceuticals (SCPH) investor relations material
scPharmaceuticals has been acquired by MannKind Corporation
scPharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Net FUROSCIX revenue reached $16 million in Q2 2025, up 99% year-over-year, with 20,200 doses filled and strong adoption in both cardiology and chronic kidney disease following the CKD launch in April 2025.
Cardiology drove most Q2 dose growth, while nephrology showed rapid prescriber uptake and is expected to contribute meaningfully in Q3 and beyond.
The number of unique prescribers rose to approximately 4,700, reflecting expansion in both cardiology and nephrology.
FUROSCIX received 3-year FDA exclusivity in October 2024, preventing approval of competing subcutaneous furosemide products until October 2025.
Development of an 80mg/1mL autoinjector is underway, with sNDA submission on track for Q3 2025, aiming to reduce COGS and boost market penetration.
Financial highlights
Q2 2025 product revenues were $16 million, up from $8.1 million in Q2 2024; cost of product revenues rose to $5 million from $2.3 million year-over-year.
Net loss for Q2 2025 was $18 million, compared to $17.1 million in Q2 2024; net loss per share was $0.34.
Cash and cash equivalents stood at $40.8 million as of June 30, 2025, down from $75.5 million at year-end 2024.
Gross to net discount for FUROSCIX was 27% in Q2, expected to approach 30% in Q3 due to Medicare Part D redesign.
Operating expenses for Q2 2025 were $30.3 million, up from $22.5 million in Q2 2024, driven by increased R&D and SG&A costs.
Outlook and guidance
Anticipates continued strong growth in nephrology and IDN segments, with nephrology expected to have a meaningful impact starting in Q3.
Medicare Part D redesign is now a tailwind, with more patients reaching out-of-pocket maximums, supporting prescription growth and fill rates.
A 3.5% price increase for FUROSCIX is effective July 1, 2025.
sNDA submission for the autoinjector is on track for Q3 2025, expected to reduce COGS by 75% and boost penetration.
Management expects continued operating losses as commercialization expands and R&D investment continues.
Plan to reach profitability given cash burn?
Impact of higher nephrology doses per Rx?
ASM program: Sales force targeting strategy?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from scPharmaceuticals
- Rapidly growing subcutaneous furosemide sees strong adoption, with major expansion ahead.SCPH
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 revenue up 33% with FDA label expansion and $175M financing, but losses increased.SCPHQ2 20241 Feb 2026
- Rising repeat prescriptions, new indications, and product innovation set the stage for rapid growth.SCPHH.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026
- Strong growth, improved access, and pipeline expansion position FUROSCIX for continued success.SCPHMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- FUROSCIX prepares for CKD launch, targeting a $3B market with strong clinical and financial momentum.SCPHStatus Update19 Jan 2026
- Q3 revenue up 24% sequentially and 164% year-over-year, with major new financing secured.SCPHQ3 202414 Jan 2026
- Label expansion, Medicare changes, and new delivery tech position FUROSCIX for strong 2025 growth.SCPHLeerink’s Global Healthcare Conference 202526 Dec 2025
- Strong revenue growth and new CKD approval set the stage for accelerated expansion in 2025.SCPHQ4 202426 Dec 2025
- Furoscix expands home-based heart failure care, with CKD approval and auto-injector launch imminent.SCPHOppenheimer 35th Annual Healthcare Life Sciences Conference 202516 Dec 2025
- Medicare redesign and CKD launch position FUROSCIX for accelerated growth in 2024-2025.SCPHTD Cowen 45th Annual Healthcare Conference16 Dec 2025
scPharmaceuticals
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage